Approved HCV Drugs
Approved HCV Drugs
Technivie Regimen Shows Good Response Rate for People with HCV Genotype 4
- Details
- Category: Approved HCV Drugs
- Published on Wednesday, 12 August 2015 00:00
- Written by Liz Highleyman
An interferon-free combination of paritaprevir, ritonavir, and ombitasvir -- the drugs in AbbVie's recently approved Technivie coformulation -- taken for 12 weeks cured more than 90% of patients with hepatitis C virus (HCV) genotype 4 in the PEARL-I trial, according to a study report in the June 20 edition of The Lancet.
Adding Ribavirin to Harvoni for Hepatitis C Increases Side Effects But Not Efficacy
- Details
- Category: Approved HCV Drugs
- Published on Friday, 26 June 2015 00:00
- Written by Liz Highleyman
Combining sofosbuvir/ledipasvir (Harvoni) with ribavirin was associated with a greater likelihood of adverse events and laboratory abnormalities, but did not significantly increase the chances of sustained response for genotype 1 chronic hepatitis patients compared to sofosbuvir/ledipasvir alone, according to an analysis of the Phase 3 ION trials described in the July edition of Hepatology.
ASCEND Study Looks at Community-based Hepatitis C Treatment
- Details
- Category: Approved HCV Drugs
- Published on Wednesday, 22 April 2015 00:00
- Written by Liz Highleyman
A new trial sponsored by the U.S. National Institutes of Health will evaluate whether primary care physicians and other health care providers such as nurse practitioners can provide interferon-free therapy for hepatitis C as effectively as hepatologists or infectious disease specialists. If successful, community-based care could greatly expand the number of people able to access treatment.
Viekira Pak Regimen Cures 100% of Genotype 1b Hepatitis C Patients with Cirrhosis
- Details
- Category: Approved HCV Drugs
- Published on Friday, 26 June 2015 00:00
- Written by AbbVie
All participants in the TURQUOISE-III trial, which enrolled HCV genotype 1b patients with compensated liver cirrhosis, achieved sustained virological response using AbbVie's Viekira Pak or "3D" regimen without ribavirin, according to a company announcement this week.
CROI 2015: Good Sofosbuvir/Ledipasvir Adherence in SYNERGY and ERADICATE Trials
- Details
- Category: Approved HCV Drugs
- Published on Friday, 10 April 2015 00:00
- Written by Liz Highleyman
Overall adherence rates ranged from 96% to nearly 100% in 2 clinical trials of sofosbuvir/ledipasvir (Harvoni) treatment in an urban population of hepatitis C and HIV/HCV coinfected patients traditionally considered difficult to treat, researchers reported at the recent 2015 Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle. Adherence dropped off over time, however, underlining the importance of short-duration therapy.
More Articles...
- Merck Plans to Discontinue Boceprevir for Hepatitis C by December 2015
- 2. Harvoni and Viekira Pak: Effective Oral Combinations for HCV Genotype 1
- 3. High Hepatitis C Treatment Cost Leads to Restrictions, Sets Off Price War
- AASLD 2014: Sofosbuvir/ Ledipasvir Cures Most Previously Treated HCV Patients with Cirrhosis
Web Design and Development by